Скачать или смотреть Aromatase Inhibitors Outshine SERMs in HR+/HER2+ Breast Cancer: ALTTO Trial Insights

Aromatase inhibitors breast cancer
HR positive HER2 positive early breast cancer
Adjuvant endocrine therapy
ALTTO trial findings
Disease-free survival DFS
Time to distant recurrence TTDR
Overall survival OS
SERMs tamoxifen vs aromatase inhibitors
San Antonio Breast Cancer Symposium SABCS 2025
Explore the latest data from the ALTTO trial showing how aromatase inhibitors improve DFS and TTDR in HR+/HER2+ early breast cancer patients without harming OS. This analysis compared aromatase inhibitors to SERMs like tamoxifen, revealing benefits across menopausal statuses and patient subgroups. Key results include a 3.6% gain in 10-year DFS and insights on ovarian function suppression in premenopausal patients. Learn about optimal adjuvant ET choices for better long-term outcomes in HER2-positive breast cancer treated with chemotherapy and anti-HER2 therapies. Presented at SABCS by Matteo Lambertini.